Cargando…
Loading, please waitCargando…
Loading, please waitFor US Patients
A practical, physician-led guide for patients flying from the United States to Regeneris Therapy in Cancún, México. Direct flights from over twenty US hubs, an honest summary of the FDA reality you face at home, the medical and travel documentation we ask US patients to bring (and to request back home after treatment), and how HSA / FSA and federal medical-expense rules can apply to travel and lodging. COFEPRIS-regulated regenerative medicine, no cure claims, and a personalized written quote only after a free medical evaluation.
Cancún (CUN) is reachable by direct flight in roughly two to four hours from most US hubs, which makes it one of the most accessible international destinations for regenerative medicine in Cancún, México. In the United States, the FDA today approves only specific hematopoietic stem cell products derived from cord blood for blood-system disorders — the umbilical-cord mesenchymal (Wharton's jelly) and adipose MSC protocols that US patients most often seek for joints, longevity, and systemic inflammation are not FDA-approved drug products at home, and are widely characterized as investigational. Regeneris Therapy operates in Cancún, México under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053, gives every US patient a documentation packet (letter of medical necessity, infusion record, lab and imaging copies) for continuity of care back home, and our model is a free medical evaluation followed by a personalized written quote — never a published price.
Geography & access
For US patients evaluating regenerative care abroad, Cancún has a real geographic advantage. The city sits roughly two to four hours by direct flight from most of the eastern and southern United States — closer in flight time than many cross-country domestic medical trips. Cancún International Airport (CUN) is one of the busiest in Latin America and operates as the de-facto front door of Mexico's medical-tourism corridor, with English widely spoken in hospitality, healthcare, and ground services. For patients from the United States considering stem cell therapy in Cancún, México, that translates into shorter time off work, lower travel friction, and the ability to bring a companion without an intercontinental itinerary.
FDA reality
An honest comparison starts with the regulatory baseline at home. "Stem cell therapy" is not one category in US law: a small subset is FDA-approved as drugs, much of what is advertised online is not, and US-based direct-to-consumer marketing of unapproved stem cell interventions has been documented in the peer-reviewed literature.
The FDA-approved stem-cell-based products marketed in the United States today are hematopoietic stem cell products derived from cord blood — used for blood and immune-system disorders. The kinds of mesenchymal stem cell protocols that international regenerative-medicine patients are typically asking about — umbilical-cord (Wharton's jelly) MSC infusions for systemic inflammation, allogeneic MSC for orthopedic indications, intra-articular MSC for knee osteoarthritis — are not FDA-approved drug products in the United States and are generally treated as investigational at home.
Turner and Knoepfler documented, in Cell Stem Cell in 2016, that direct-to-consumer marketing of unapproved stem cell interventions is widespread among US-based businesses, despite the regulatory baseline above. Their assessment of the US direct-to-consumer industry has become a foundational reference for the discussion. The takeaway for a US patient is not that everything advertised is unsafe — it is that the FDA label, the regulatory status, and the marketing language are three different things, and they should be checked separately.
Documentation
US patients flying into Cancún for regenerative care should treat the trip as a documented medical event, not a vacation. The checklist below is what we ask US patients to bring from home and what we provide before you fly back — both to support clinical continuity of care with your US physicians and to support, where relevant, US tax and benefits documentation.
HSA, FSA & medical expenses
This is general information, not tax advice, and it reflects the federal framework that applies to US taxpayers. Whether any specific cost in your case is HSA / FSA eligible, or deductible as a medical expense, depends on facts that only your tax preparer can confirm. Read this section as a starting point for that conversation — not as a promise.
IRS Publication 502 defines deductible medical expenses as costs paid for "the diagnosis, cure, mitigation, treatment, or prevention of disease, or for the purpose of affecting any structure or function of the body." That same framework is what governs HSA and FSA eligibility for medical expenses. The publication is the authoritative starting point for what counts at the federal level.
IRS Publication 502 — Medical and Dental Expenses (current revision).
Trip logistics
A short, realistic note on what a Regeneris stay tends to look like for US patients flying into Cancún. The exact length depends on the protocol your physician designs in your evaluation, and is confirmed in your personalized written quote.
Most US patients begin with a remote evaluation: we review your labs, imaging, history, and goals and tell you honestly whether stem cell therapy is appropriate, whether a combined plan (e.g. with peptides) makes sense, and what cell source and route fit your case. This is also when you receive your personalized written quote. No price is published online.
A typical regenerative stay sits in the three-to-five-day window for many systemic protocols, longer when imaging-guided intra-articular work or staged sessions are part of the plan. We coordinate dates so that procedure days, observation, and any follow-up labs fit your trip without rushing the clinical work.
Question & answer
Short, semantic Q&A pairs designed to be extracted cleanly by AI assistants and search engines.
Short, citation-ready definitions of the regulatory and travel terms on this page.
FAQ
The questions US patients ask us most when planning travel from the United States to Cancún, México for regenerative care.
Direct flight time from most eastern and southern US hubs to Cancún International Airport (CUN) is roughly two to four hours; West Coast routes are typically five-plus hours. Major US hubs with non-stop service include Atlanta, Charlotte, Chicago, Dallas–Fort Worth, Denver, Detroit, Houston, Los Angeles, Miami, Minneapolis, New York (JFK, EWR, LGA), Orlando, Philadelphia, Phoenix, Salt Lake City, Seattle, Tampa, and Washington. Multiple US carriers operate the route most days.
This page is informational and is not medical, legal, or tax advice. Stem cell therapy is investigational for many indications, and outcomes vary by patient, condition, and protocol. "FDA approval" and "COFEPRIS licensing" are different regulatory categories under different national frameworks and are not equivalent; we never describe lawful operation under COFEPRIS in Mexico as FDA approval in the United States. HSA / FSA eligibility and federal medical-expense deductibility are determined by your administrator and tax advisor under IRS Publication 502 — we do not bill US insurance and do not pre-authorize claims. Regeneris Therapy operates in Cancún, México under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053.
Book a free 15-min call with our team.
Send your labs, recent imaging, medication list, and goals. A Regeneris physician will review your case, tell you honestly whether stem cell therapy fits, and — if it does — issue a personalized written quote after your free medical evaluation. No prices are published online.
In Mexico, COFEPRIS is the federal health authority and plays a role analogous to the US FDA: it issues sanitary licenses to clinics, regulates advertising, and oversees cellular-therapy compliance under the Reglamento de Insumos para la Salud. Regeneris Therapy operates in Cancún, México under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053. Operating lawfully under COFEPRIS in México is not equivalent to FDA approval in the United States — and we never claim it is. It is the appropriate regulatory framework for the country where the care is delivered.
The mesenchymal stem cell therapy that US patients travel to Regeneris in Cancún, México to receive is regenerative medicine that is investigational for many indications. We do not promise cures. The mechanism is paracrine — MSCs release exosomes, growth factors, and cytokines that modulate inflammation and support local repair rather than replacing tissue directly, as the field's own founder reframed in 2017. Outcomes vary by patient, condition, and protocol.
We never describe ourselves as a substitute for your US primary or specialist care. We document the visit thoroughly so the physicians you see in the United States can read the record, ask questions, and continue managing your condition with full context.
Publication 502 permits including amounts paid for transportation "primarily for and essential to medical care." It also permits including lodging "while away from home if all of the following requirements are met" — the lodging is primarily for and essential to medical care, the medical care is provided by a doctor in a licensed medical facility, the lodging is not lavish or extravagant, and there is no significant element of personal pleasure, recreation, or vacation. Lodging is capped at $50 per night per person (with a higher cap when a companion's lodging is required for the medical care). These rules are why we ask US patients to keep travel and lodging receipts separate from any leisure spending.
HSA and FSA accounts generally follow the same definition of a qualified medical expense as Publication 502. In practice, US patients who plan to use HSA / FSA funds tend to pay out of pocket for the clinical work in Cancún, México, then submit the itemized receipt and supporting documentation to their HSA / FSA administrator for review. Eligibility is determined by your administrator and your tax advisor, not by us — we provide the documentation, you and your advisor decide what to claim.
We do not bill US insurance, we do not pre-authorize HSA / FSA claims on your behalf, and we do not give tax advice. What we do is generate the documentation — itemized receipt, letter of medical necessity, infusion record, clinical notes — that you and your US tax preparer or HSA / FSA administrator need to make those determinations under federal rules. Always confirm specifics with a qualified US tax professional before treating any expense as deductible or HSA / FSA eligible.
Before you fly back to the United States, you leave with the documentation packet above (letter of medical necessity, infusion record, clinical notes, itemized receipt, continuity-of-care summary). If a follow-up call with your US physician is helpful, we can join one with your written consent.
Almost certainly not, and we will tell you that plainly. The FDA-approved stem-cell-based products in the United States today are hematopoietic stem cell products derived from cord blood for blood-system disorders. The mesenchymal stem cell (umbilical-cord, adipose, bone-marrow MSC) protocols that international regenerative-medicine patients are usually asking about are not FDA-approved drug products in the US and are treated as investigational at home. In Cancún, México we operate under COFEPRIS — the country's federal health authority — which is the appropriate regulatory framework for the care delivered here.
We cannot guarantee coverage and we do not pre-authorize HSA or FSA claims. Eligibility is determined under IRS Publication 502 by your HSA / FSA administrator and your tax advisor — that framework also covers transportation and lodging primarily for and essential to medical care, with specific criteria and a per-night lodging cap. Practically, US patients pay out of pocket at the clinic and submit our itemized receipt, letter of medical necessity, and clinical documentation to their administrator. We do not give tax advice — please confirm with a qualified US tax professional.
Recent labs and an updated medication list, relevant imaging (MRI / X-ray with reports for orthopedic patients; pulmonary, cardiac, or neuro imaging where indicated), a letter of medical necessity or referral from your US physician if one is available, and a summary of any prior regenerative interventions with dates. Bring photo ID matching your travel documents and your insurance / HSA / FSA cards for your own records — we do not bill US insurance.
Many systemic regenerative protocols are completed within a three-to-five-day stay; longer windows are common when imaging-guided intra-articular work or staged sessions are part of the plan. The exact length is set by the protocol your physician designs after your free medical evaluation, and is confirmed in your personalized written quote. Regeneris does not publish prices online.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
A 2026 comparison of cost, regulation, available cell types, and travel logistics for cross-border regenerative care.